What Ionis Pharmaceuticals Bears Saw Before The Fall

Ionis Pharmaceuticals grabbed headlines when the FDA cleared Tryngolza to treat severe hypertriglyceridemia, expanding it from a rare disease niche to a broader metabolic setting and sparking a sharp after-hours price jump. Holding Ionis Pharmaceuticals from the start of the year would have meant a 44.4% loss, including dividends. If you had chosen to buy on 1 January, how should you now weigh that setback against fresh expectations for Tryngolza and the rest of the pipeline?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Ionis Pharmaceuticals is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced.

The Two Ionis Pharmaceuticals Stories Investors Had To Choose Between

The shares cost US$79.11 at the start of the period, and anyone looking at Ionis Pharmaceuticals then had to decide which of two stories felt more convincing.

The bullish Narrative put Fair Value at US$96, based on the idea that revenue could climb 27.7% a year and that profit margins might move from a loss to 19.0%. This view was supported by a wave of potential blockbuster launches across neurological, cardiovascular, and rare conditions.

The bearish view anchored Fair Value at US$69.48, accepting revenue growth of 17.3% but emphasizing risks that expanding Olezarsen into severe hypertriglyceridemia could require lower pricing and put pressure on future earnings.

What The Results Changed For The Ionis Pharmaceuticals Story

The FDA approval of Tryngolza for severe hypertriglyceridemia backed the bullish Ionis Pharmaceuticals pitch that wider indications could support meaningful top-line potential. The measured results told a different story. Revenue moved from US$452.0m in Q2 2025 to US$267.9m in Q2 2026, while profit swung from a gain to a loss and net margin fell from 27.3% to a 42.8% loss. That mix of traction and weaker profitability cut both ways.

The lesson is simple. When a thesis leans on future profit improvement, track not just new approvals but also the direction of net income and margin each quarter, and test whether they are actually moving toward the story being sold.

What Ionis Pharmaceuticals' Drop Now Asks You To Believe

Ionis Pharmaceuticals trades at US$44.27, after the shares fell 44.4% from the start of the year. The selected Narrative’s Fair Value estimate sits above that price and rests on the idea that execution in neurology and severe hypertriglyceridemia can eventually outweigh pipeline setbacks.

To treat the fall as an opening rather than a warning, a buyer today would need confidence that TRYNGOLZA, ZANVASTRO and key partnered programs can reach the commercialization and adoption levels the Narrative assumes.

"The main factor that has to go right is successful commercialization and adoption of core wholly owned assets, such as TRYNGOLZA for severe hypertriglyceridemia and ZANVASTRO and other neurology medicines, supported by Ionis Pharmaceuticals maintaining its 2026 revenue and TRYNGOLZA sales guidance."

The price and this Narrative do not agree. → Uncover what this Narrative says Ionis Pharmaceuticals is actually worth

Go Straight To The Source

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 31% below our estimate - uses structured improvement initiatives to lift margins while integrating higher value valve assets.
• Company 2 - 33% below our estimate - expands high horsepower engine capacity to meet long-duration data center and power needs.
• Company 3 - 36% below our estimate - grows emerging market payment volumes while automating services to support stronger margins.

That is three of the list. See all 33 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com